Alexion likely to deliver beat and raise results, says Stifel Stifel expects Alexion to deliver beat and raise results for the rest of FY14. The firm thinks the stock's valuation is becoming increasingly attractive, and believes that the company has a number of upcoming positive catalysts. It keeps a Buy rating on the stock.
Alexion announces $500M share repurchase program Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.